MedinCell S.A. (LON:0ACH)

London flag London · Delayed Price · Currency is GBP · Price in EUR
23.66
-0.28 (-1.17%)
At close: Feb 11, 2026
Market Cap694.34M +79.8%
Revenue (ttm)28.31M +145.8%
Net Income-17.41M
EPS-0.55
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,834
Average Volume16,035
Open23.64
Previous Close23.93
Day's Range22.94 - 24.12
52-Week Range12.02 - 39.38
Beta1.06
RSI41.47
Earnings DateJun 16, 2026

About MedinCell

MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults; and mdc-CWM, a sustained-release formulation of celecoxib in Phase III tria... [Read more]

Industry Pharmaceutical Preparations
Founded 2003
Employees 145
Stock Exchange London Stock Exchange
Ticker Symbol 0ACH
Full Company Profile

Financial Performance

In fiscal year 2025, MedinCell's revenue was 27.73 million, an increase of 132.12% compared to the previous year's 11.95 million. Losses were -18.44 million, -26.36% less than in 2024.

Financial numbers in EUR Financial Statements